Is the CSL share price a buy? Here’s a top broker’s view
Image source: Getty Images
The CSL Ltd (ASX: CSL) share price is down 15% since the start of 2025 and 20% in the last six months, as the chart below shows. After a sizeable decline, interested investors may be wondering whether this ASX healthcare share is an opportunity.
To answer that question, we’re going to look at what the broker UBS thinks of the large ASX biotech share.
Aside from the overall market volatility, investors appear to be worried about what changes to the healthcare sector may occur in the US under the new Trump administration.
Let’s get into the analysis.
UBS view on CSL shares
The broker said that drugs, blood products and vaccines are exempt from US reciprocal tariffs so far, but President Trump has made it clear…
